Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The hedgehog pathway is a major regulator of cell growth and differentiation during embryogenesis and early development. The literature suggests that variations in this pathway's genes play a role in tumor progression and response to therapy. This study aimed to assess the correlation between the expression levels of selected genes of this pathway and the progression-free and overall survival of ovarian cancer patients. Using the database Kaplan-Meier plotter, which includes the gene expression and survival data of 1565 ovarian cancer patients, higher expression levels of the genes , , , and displayed better survival correlations, while , , and correlated with adverse outcomes. Further dissection revealed a differential impact of the genes in specific clinical-histopathological categories. Notably, higher expression levels of were associated with a negative impact on ovarian cancer patients under many clinical-histopathological aspects. These results shed new light on the role of these genes in the chemoresponsiveness of ovarian cancer, especially , which could be considered a novel indicator for poor prognosis in epithelial ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12193027 | PMC |
| http://dx.doi.org/10.3390/ijms26125888 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.
Med Sci Monit
August 2025
Independent Laboratory of Translational Medicine, Medical University of Lublin, Lublin, Poland.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality, with high rates of recurrence and chemoresistance. Advances in understanding the molecular biology of EOC, particularly BRCA mutations and homologous recombination deficiency (HRD), have led to more targeted therapies. This review provides an updated summary of systemic treatments for EOC, with an emphasis on personalized therapy approaches and emerging therapeutic strategies.
View Article and Find Full Text PDFClinical value of preoperative serum calcium level in predicting deep infiltrative endometriosis among ovarian endometrioma.
Ann Med
December 2025
Department of Gynecology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Objective: To evaluate preoperative serum calcium levels and their association with deep infiltrating endometriosis (DIE) in ovarian endometrioma.
Design: A retrospective, observational cohort study.
Participants: A total of 2,557 women who underwent surgery for benign ovarian tumors were initially enrolled.
The Promising Role of PKM2 in the Diagnosis and Prognosis of Ovarian Cancer.
Anticancer Agents Med Chem
September 2025
Department of Pharmaceutical Chemistry, Maharana Pratap College of Pharmacy, Kanpur-209217, Uttar Pradesh, India.
PKM2 has emerged as a critical biomarker with the potential to enhance both diagnostic accuracy and therapeutic strategies in ovarian cancer. Due to its high fatality rate and difficulty identifying early signs, ovarian cancer remains a major global health concern. Biomarkers, particularly PKM2, provide targeted therapeutic methods and early detection.
View Article and Find Full Text PDFMirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.
Int J Gynecol Cancer
July 2025
University of California, Los Angeles, Department of Gynecologic Oncology, Los Angeles, CA, USA.
Objective: To evaluate prescribing patterns, toxicities, and outcomes among patients receiving mirvetuximab for platinum-resistant ovarian cancer.
Methods: This retrospective study included patients with platinum-resistant ovarian cancer with high folate receptor alpha expression treated with mirvetuximab at a single institution (2018-2023). Patients were categorized based on treatment immediately preceding mirvetuximab: the taxane group received taxane treatment; the non-taxane group received other therapy.
Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials.
Eur J Surg Oncol
September 2025
Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil. Electronic address:
Background: Ovarian cancer has the highest mortality among gynecologic malignancies. Despite cytoreductive surgery (CRS) and systemic therapy, peritoneal recurrence remains common. Hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated chemotherapy directly to the peritoneal cavity, enhancing local cytotoxicity and offering a potential therapeutic strategy.
View Article and Find Full Text PDF